Media Contact: Alexandra Curbelo
Wragg & Casas Public Relations
1221 Brickell Avenue, Suite 730
Miami, Fl. 33131
305-372-1234 ex.124
Email: acurbelo@wraggcasas.com

**For Immediate Release**

# BIOHEART ANNOUNCES AGREEMENT WITH ANOSIS TO DISTRIBUTE PRODUCTS IN THE MIDDLE EAST

---

**Sunrise, FL – October 25, 2013 –** Bioheart, Inc. (BHRT.OB), a biotech company focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage as well as severe peripheral vascular disease announces that it has entered into an agreement with Anosis, a company organized in Turkey. According to the distribution agreement, Anosis will distribute Bioheart therapies in Turkey, Azerbajian, Kazakhistan, Turkmenistan, Georgia and Iraq.

Anosis is a large distribution company focused on bringing medical devices and regenerative medicine to patients in the Middle East. Bioheart therapies including MyoCell™ (muscle derived stem cells) and AdipoCell™ (adipose derived stem cells) will be used to treat a variety of indications including heart disease, limb ischemia, COPD, diabetes, and more. Anosis has successfully completed a study of 50 patients suffering from critical limb ischemia using the adipose derived stem cells. Results from this study are not published yet. In previous Bioheart studies for patients with chronic non-healing ulcer wounds due to critical limb ischemia, 75% of the patients have avoided limb amputation.

"We are thrilled to expand our relationship with Anosis and provide our cutting edge therapies to additional areas in the Middle East. Stem Cells are naturally anti-

inflammatory and pro-healing and we believe that our therapies can successfully be utilized in many degenerative diseases," said Kristin Comella, CSO of Bioheart, Inc.

**About Bioheart, Inc**

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2012, and its Quarterly Report on Form 10-Q for the quarter ended June 31, 2013.